Roxadustat
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Roxadustat: From Renal Anemia to Dry Eye Syndrome
One-Sentence Summary
Roxadustat is a HIF prolyl-hydroxylase inhibitor referenced in the evidence pack as a treatment for renal anemia, though formal EU regulatory indication data is unavailable (the product is currently not marketed in the EU). The TxGNN model predicts it may be effective for Dry Eye Syndrome, but this is currently supported by only 1 clinical trial (observational, low direct relevance) and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — EU authorization data absent (renal anemia mentioned only indirectly in trial context, not from a regulatory source) |
| Predicted New Indication | Dry Eye Syndrome |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L4 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on the trial context included in this evidence pack, Roxadustat (FG-4592) is a HIF prolyl-hydroxylase inhibitor (HIF-PHI) referenced as a treatment for renal anemia in chronic kidney disease, alongside erythropoietin (EPO). No formal EU marketing authorization or approved indication text is on file for this product.
The single piece of supporting evidence, NCT06287879, is an observational (non-interventional) study examining meibomian gland structure and function in renal anemia patients who also present with dry eye symptoms — it does not test whether Roxadustat treats dry eye syndrome. The trial’s own relevance grading (Grade C) confirms this is an indirect association only: patients on Roxadustat for their kidney disease happened to be evaluated for a co-occurring eye condition.
Mechanistically, the rationale proposed is that the HIF pathway may play a role in hypoxia-related regulation of lacrimal and meibomian gland function, which could theoretically link HIF stabilization to tear-film/ocular surface biology. However, this is a theoretical extrapolation with no causal or interventional evidence — the repurposing rationale itself explicitly states “無因果證據” (no causal evidence).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06287879 | N/A | Unknown | 50 | Observational study of meibomian gland function/morphology in renal anemia patients (commonly treated with EPO or Roxadustat) presenting with dry eye symptoms. Does not directly test Roxadustat’s efficacy for dry eye syndrome. |
Literature Evidence
Currently no related literature available.
EU Market Information
No EU marketing authorizations are currently registered for this product (market status: not marketed; 0 licenses on file).
Safety Considerations
Please refer to the SmPC for safety information.
(Note: Detailed TFDA/EMA-equivalent product warnings and contraindications are flagged as a Blocking data gap — DG001 — pending retrieval and parsing of the official product label.)
Conclusion and Next Steps
Decision: Hold
Rationale: The only supporting evidence is a single, low-relevance observational trial (Grade C) that does not directly test Roxadustat’s efficacy for dry eye syndrome, and no literature evidence exists. Combined with blocking data gaps in mechanism of action and product safety information, this candidate does not currently meet the evidence bar to proceed past initial screening (Decision Stage S0).
To proceed, the following is needed:
- Mechanism of action (MOA) data from DrugBank (DG002)
- Official product warnings/contraindications from a regulatory source (DG001) — required before any safety (S1) evaluation
- An interventional/efficacy trial directly testing Roxadustat in dry eye syndrome patients (current evidence is purely observational and in a different patient population context)
- Clarification of regulatory status, since the drug is not currently marketed in the EU
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.